Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 11/20 | 0.66 |
| ▸ | LTA4H | P09960 | 5/20 | 0.65 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9554742 | 0.89 | ACE (0.81) | ACELTA4HACE2 | |
| SCHEMBL9554734 | 0.89 | ACE (0.81) | ACELTA4HACE2 | |
| SCHEMBL6367888 | 0.86 | ACE (0.66) | ACELTA4H | |
| SCHEMBL11565565 | 0.86 | ACE (0.66) | ACELTA4HACE2 | |
| SCHEMBL3726264 | 0.85 | ACE (0.70) | ACELTA4H | |
| SCHEMBL3726263 | 0.85 | ACE (0.70) | ACELTA4H | |
| SCHEMBL11497547 | 0.85 | ACE (0.66) | ACELTA4HACE2 | |
| SCHEMBL5900809 | 0.85 | ACE (0.70) | ACELTA4H | |
| SCHEMBL6787617 | 0.85 | ACE (0.76) | ACELTA4HACE2 | |
| SCHEMBL6436643 | 0.85 | ACE (0.70) | ACELTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060111553-A1 | Novel thrombin inhibitors, the preparation and use thereof | ABBOTT GMBH & CO. KG (DE) | 2006-05-25 | — | — | US | disclosed |
| US-20030004308-A1 | Novel thrombin inhibitors, the preparation and use thereof | BOHM HANS-JOACHIM (DE) | 2003-01-02 | — | — | US | disclosed |
| US-6455671-B1 | COMPOUND FOR USE IN THE TREATMENT OF THROMBOSIS | ABBOTT LABORATORIES | 2002-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111553-A1 | Novel thrombin inhibitors, the preparation and use thereof | TFPI, F2, TFPI2 | ACE 98/4885LTA4H 210/4885ACE2 156/4885 |
| US-20030004308-A1 | Novel thrombin inhibitors, the preparation and use thereof | TFPI, SERPINC1, F2 | ACE 110/4885LTA4H 253/4885ACE2 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.